↓ Skip to main content

Dove Medical Press

Article Metrics

What is this page? Embed badge

The role of delamanid in the treatment of drug-resistant tuberculosis

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
7 tweeters

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
129 Mendeley
Summary Twitter Dimensions citations
Title
The role of delamanid in the treatment of drug-resistant tuberculosis
Published in
Therapeutics and Clinical Risk Management, May 2015
DOI 10.2147/tcrm.s71076
Pubmed ID
25999726
Authors

Derek Sloan, Joe Lewis

Abstract

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Brazil 1 <1%
Unknown 126 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 21 16%
Student > Master 19 15%
Student > Ph. D. Student 16 12%
Other 9 7%
Researcher 8 6%
Other 19 15%
Unknown 37 29%
Readers by discipline Count As %
Medicine and Dentistry 28 22%
Biochemistry, Genetics and Molecular Biology 17 13%
Chemistry 12 9%
Pharmacology, Toxicology and Pharmaceutical Science 10 8%
Agricultural and Biological Sciences 7 5%
Other 14 11%
Unknown 41 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2015.
All research outputs
#5,694,500
of 22,803,211 outputs
Outputs from Therapeutics and Clinical Risk Management
#278
of 1,263 outputs
Outputs of similar age
#66,870
of 264,364 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#12
of 42 outputs
Altmetric has tracked 22,803,211 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,263 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,364 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.

This page is hosted by Altmetric on behalf of Dove Medical Press.